Mitoxantrone (Novantrone)
Mitoxantrone (Novantrone) is a medication administered by IV infusion, approximately 5 to 15 minutes infusion every 3 months, for the treatment of secondary progressive MS, relapsing forms of MS, and worsening relapsing remitting MS. Mitoxantrone is a topoisomerase II inhibitor and has been shown to inhibit B cell, T cell, and macrophage proliferation in vitro. It also produces an impairment of antigen presentation and secretion of interferon gamma, TNFa, and IL-2.
Mitoxantrone is rarely used in MS due to its significant risk profile.
Additional Information
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
